Analizė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 10,635,635 | 12,133,490 | 14,149,214 | 15,756,713 | 15,946,578 | 17,467,221 | 18,638,793 | 20,273,230 |
| Profit before tax | 681,013 | 1,089,352 | 1,700,302 | 1,490,571 | 1,374,575 | 1,297,490 | 1,462,145 | 1,805,759 |
| Net profit | 598,905 | 965,716 | 1,442,654 | 1,259,341 | 1,160,286 | 1,091,421 | 1,236,338 | 1,505,915 |
| Equity | 4,454,392 | 5,259,731 | 6,632,385 | 7,719,726 | 8,380,012 | 8,971,433 | 8,468,118 | 8,774,033 |
| Liabilities | 1,451,913 | 1,092,624 | 2,084,741 | 2,035,895 | 558,085 | 1,384,339 | 747,144 | 999,672 |
| Non-current assets | 2,292,783 | 2,321,764 | 3,903,477 | 3,365,879 | 3,020,467 | 2,722,508 | 2,476,697 | 2,211,796 |
| Current assets | 3,603,819 | 4,020,986 | 4,773,253 | 6,321,672 | 5,767,442 | 7,563,038 | 6,666,403 | 7,489,724 |
| Total assets | 5,896,602 | 6,342,750 | 8,676,730 | 9,687,551 | 8,787,909 | 10,285,546 | 9,143,100 | 9,701,520 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 2,221,687 | 2,683,403 | 2,875,289 |
| Social insurance contributions | - | - | - | - | - | 322,825 | 344,317 | 372,485 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +19.9% | +14.1% | +16.6% | +11.4% | +1.2% | +9.5% | +6.7% | +8.8% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 10.2% | 15.2% | 16.6% | 13.0% | 13.2% | 10.6% | 13.5% | 15.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 13.4% | 18.4% | 21.8% | 16.3% | 13.8% | 12.2% | 14.6% | 17.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.6% | 8.0% | 10.2% | 8.0% | 7.3% | 6.2% | 6.6% | 7.4% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 6.4% | 9.0% | 12.0% | 9.5% | 8.6% | 7.4% | 7.8% | 8.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.2 | 0.3 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 103,342 | 131,173 | 331,622 | 365,020 | 355,686 | 374,967 | 394,472 | 448,853 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Analizė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-04-25 | 2026-04-26 | 0.08 |
| 2026-03-27 | 2026-03-27 | 34.30 |
| 2026-03-17 | 2026-03-24 | 34.30 |
Analizė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-19 | 2025-01-27 | 0.08 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Analize, UAB (code 132797911) is a Private Limited Liability Company operating in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €20.27M, up from €18.64M in 2024 and €17.47M in 2023, showing a steady two-year expansion. Net profit increased from €1.09M in 2023 to €1.24M in 2024 and €1.51M in 2025, while the profit margin improved from 6.2% to 6.6% and then to 7.4%. The 2025 result also corresponds to a strong ROE of 17.2% and ROA of 15.5%, supported by asset turnover of 2.09x. The balance sheet remained conservative, with total assets of €9.70M, equity of €8.77M and liabilities of €999.7K in 2025. The equity ratio stood at 90.4% and debt-to-equity at 0.11, indicating limited leverage. Revenue per employee was €450.5K and profit per employee €33.5K, suggesting high productivity.